Treatment of Enterobacterales Spontaneous Bacterial Peritonitis with Piperacillin/Tazobactam

Efficacy and Recommendations

Piperacillin/tazobactam is effective for treating Enterobacterales spontaneous bacterial peritonitis (SBP), particularly for community-acquired and healthcare-associated SBP in areas with low prevalence of multidrug-resistant organisms (MDROs), as recommended by the European Association for the Study of the Liver (EASL) 1, 2
The European Association for the Study of the Liver (EASL) guidelines recommend piperacillin/tazobactam as a primary approach for healthcare-associated SBP in areas with low prevalence of MDROs 1, 2
Piperacillin/tazobactam has broad-spectrum activity against gram-positive, gram-negative, and anaerobic organisms, making it suitable for empiric treatment of SBP where Enterobacterales are common causative pathogens 3
Piperacillin/tazobactam can be used as an alternative to third-generation cephalosporins for community-acquired SBP 2, 4

For community-acquired SBP, first-line options include third-generation cephalosporins or piperacillin/tazobactam, with a treatment duration of typically 5-7 days after adequate clinical response 2, 3, 4
For healthcare-associated SBP in areas with low MDRO prevalence, piperacillin/tazobactam is recommended 1, 2

Resolution of SBP should be confirmed by demonstrating a decrease of ascitic neutrophil count to <250/mm³, with a second paracentesis after 48 hours of treatment recommended to assess response 5, 6
Adding intravenous albumin (1.5 g/kg at diagnosis, followed by 1 g/kg on day 3) significantly reduces the risk of hepatorenal syndrome and improves survival, particularly in patients with baseline serum bilirubin ≥68 μmol/L or creatinine ≥88 μmol/L 5, 8

Bacterial resistance patterns are continuously changing, necessitating awareness of local resistance profiles, which may impact the efficacy of piperacillin/tazobactam 2, 4
The prevalence of ESBL-producing Enterobacterales may impact the efficacy of piperacillin/tazobactam, though recent evidence suggests it may still be effective against some ESBL producers 3